Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03245736 · ClinicalTrials.gov registry record · Phase 2
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
A Phase 2 study of Prostate Cancer and Bladder Cancer, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 4
- Study locations
NCT03245736: Completed Phase 2 study of Prostate Cancer and Bladder Cancer, sponsored by Seagen.
NCT03245736 is a Phase 2 study of Prostate Cancer and Bladder Cancer that has completed, run by Seagen. The registered enrollment target is 5 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03245736, a Phase 2 study of Prostate Cancer and Bladder Cancer, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
Primary Outcome
An adverse event (AE) is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment emergent adverse event (TEAE) is an AE occurring on or after the first dose of study medication or worsening during treatment period.
Conditions Studied
Interventions
- DRUG Tisotumab Vedotin
Study Locations (4)
Other
- Johann de Bono - Chelsea
- Beatson Cancer Centre - Glasgow
- Fiona Thistlethwaite - Manchester
Florida
- Brian Slomovitz - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-08-23 |
| Est. Completion | 2019-01-10 |
| Phase | Phase 2 |
What the finished NCT03245736 record still lists
NCT03245736 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (99% lower).
The record links to 8 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tisotumab Vedotin is the first listed.
NCT03245736 reports a single indexed study location in Other, Florida.
Frequently Asked Questions
What is clinical trial NCT03245736 about?
NCT03245736 is a clinical study titled "Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.". The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
What is the current status of trial NCT03245736?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-08-23. Estimated completion is 2019-01-10.
What conditions does trial NCT03245736 study?
This clinical trial studies the following conditions: Prostate Cancer, Bladder Cancer, Squamous Cell Carcinoma of the Head and Neck, Lung Cancer, Non-Small Cell, Esophagus Cancer.
What interventions are being tested in trial NCT03245736?
The interventions under investigation include: Tisotumab Vedotin (DRUG).
Who is sponsoring clinical trial NCT03245736?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03245736 being conducted?
This trial has 4 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03245736's enrollment target sits among peer trials
5 734th of 735 higher than 2 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI